Highest-materiality recent filing
NeuroPace reports 2026 annual meeting voting results; directors elected, auditor ratified
Lisa Andrade and Scott Huennekens elected as Class II directors to serve until 2029 annual meeting.
NeuroPace Q1 RNS rev $21.7M (+19.5%); raises FY26 rev guidance to $99-101M
RNS System revenue $21.7M (+19.5% YoY); total revenue $22.1M including $0.1M DIXI Medical.
NeuroPace Q4 rev $26.6M (+24%), FY25 rev $100M (+25%); guides FY26 $98-100M
Q4 2025 revenue $26.6M (+24% YoY); RNS System revenue $22.4M (+26% YoY); gross margin 77.4%.
NeuroPace reports record Q3 revenue $27.4M (+30% YoY); raises FY2025 guidance
Record quarterly revenue of $27.4M, up 30% YoY; RNS System revenue $22.6M (+31% YoY).
NeuroPace posts Q2 revenue $23.5M (+22% YoY); raises FY2025 revenue and margin guidance
Revenue grew 22% YoY to $23.5M; RNS System revenue up 16% in Q2.
NeuroPace names Patrick Williams as CFO; Rebecca Kuhn departs after 25 years
Rebecca Kuhn stepped down as CFO on June 20, 2025; will serve as Senior Strategic Advisor through June 19, 2026.
NeuroPace stockholders re-elect directors Becker and Fischer, ratify PwC as auditor for FY2025
Joel Becker re-elected with ~19.7M votes for (99.4%); broker non-votes 7.7M.
NeuroPace secures $75M credit facility, refinances existing $60M term loan with MidCap
New $60M term loan and $15M revolver mature June 4, 2030; proceeds repaid $61.9M to CRG.
NeuroPace NAUTILUS study meets safety endpoint; primary efficacy miss but significant in subgroup
Primary safety endpoint met: low rate of serious adverse events related to device/implant procedure.
NeuroPace reports record Q1 revenue $22.5M (+24% YoY), raises FY2025 guidance to $93-97M
Record quarterly revenue $22.5M, up 24% YoY; RNS System revenue up 29% excluding NAUTILUS study implants.
NeuroPace sees minimal tariff impact, reaffirms 2025 gross margin guidance
Expects minimal impact from international trade tariffs on operations and financial results.
NeuroPace drops SEEG distribution deal to focus on core RNS System; reaffirms 2025 guidance
Terminated exclusive DIXI Medical SEEG distribution; wind down begins Q4 2025 through Q1 2026.
NeuroPace reports Q4 revenue $21.5M (+19% YoY); guides FY2025 revenue $92-96M
Q4 2024 revenue $21.5M (+19% YoY); full year revenue $79.9M (+22%).
NeuroPace completes repurchase of 5.27M shares from KCK Ltd., terminates ATM program
Repurchased 5,270,845 shares of common stock from KCK Ltd., allowing an organized sale of KCK's entire stake.
NeuroPace announces public offering of 6.5M shares at $10; to repurchase $49.5M in shares from KCK
Offers 6,500,000 shares at $10.00 per share; net proceeds expected ~$60.6M.
NeuroPace to repurchase 17.5% stake from KCK at equity offering price
Agreed to repurchase all shares held by KCK, representing ~17.5% of outstanding common stock.
NeuroPace issues 2025 revenue guidance $92M-$96M; 3-year CAGR target 20%+
2025 revenue guidance $92M-$96M (15.5%-20.5% YoY growth); gross margin 73%-75%; total OpEx $92M-$95M.
NeuroPace to present at J.P. Morgan Healthcare Conference; no financial updates
Presentation at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025 at 4:30 p.m. PT.
NeuroPace Reports Preliminary 2024 Revenue Above Guidance and Appoints Scott Huennekens to Board
Preliminary unaudited Q4 2024 revenue expected $21.0M-$21.5M (17-19% growth vs Q4 2023), full year $79.4M-$79.9M (21-22% growth), above initial guidance of $73M-$77M.
NeuroPace Q3 revenue $21.1M (+28% YoY); raises FY2024 guidance to $78-80M
Record quarterly revenue $21.1M vs $16.4M Q3 2023, driven by RNS System sales.
NeuroPace Q2 revenue $19.3M (+17% YoY); raises FY2024 guidance to $76-78M
Revenue $19.3M (17% YoY) vs $16.5M; net loss $7.5M vs $9.1M prior year.
NeuroPace stockholders elect three Class III directors and ratify PwC as auditor
Uri Geiger elected with 10,710,133 for, 363,203 withheld, 7,926,126 broker non-votes.
NeuroPace Q1 revenue $18.1M (+25% YoY), net loss $8.9M; loan maturity extended to Sept 2026
Revenue $18.1M vs $14.5M in Q1 2023, driven by RNS System and DIXI Medical sales.
NeuroPace reports record 2023 revenue $65.4M (+44% YoY); guides 2024 revenue $73M-$77M
Record FY 2023 revenue $65.4M (+44% YoY); Q4 revenue $18.0M (+41% YoY). Net loss improved to $33.0M from $47.1M.
Irina Ridley resigns as CLO and Corporate Secretary; last day of employment is March 6, 2024.
NeuroPace preliminary Q4 rev $17.5-18.0M (+37-41% YoY); NAUTILUS trial completed early
Preliminary Q4 2023 revenue $17.5-18.0M, up 37-41% YoY; full year 2023 revenue $64.9-65.4M, up 43-44% YoY, well above initial guidance of $50-52M.
NeuroPace enters $3.7M collaboration with Rapport for Phase 2a trial of RAP compound
Agreement with Rapport Therapeutics to support Phase 2a trial of GAMA 8 Receptor-Associated Protein (RAP) compound.
NeuroPace Q3 revenue $16.4M (+47% YoY), raises FY2023 guidance to $62.5-$63.5M
Revenue $16.4M (+47% YoY); net loss $7.3M vs $11.8M a year ago.
NeuroPace Q2 revenue $16.5M (+62% YoY); raises FY 2023 guidance to $59-61M
Q2 revenue $16.5M, up 62% YoY and 14% QoQ; net loss narrowed to $9.1M from $12.7M YoY.
NeuroPace grants CEO Joel Becker option for 380,424 shares as inducement to join
Compensation Committee approved 2023 Inducement Plan reserving 380,424 shares for awards to new employees.
NeuroPace CEO Michael Favet resigns; Joel Becker appointed as new CEO effective July 10, 2023
Michael Favet resigns as CEO and Board member effective July 10, 2023; will provide consulting services for 12 months at $600/hour.
NeuroPace stockholders elect two Class II directors, ratify PwC as auditor at 2023 annual meeting
Elected Lisa Andrade (8,506,611 for, 432,292 withhold) and Joseph Lacob (8,475,094 for, 463,809 withhold) as Class II directors until 2026.
NeuroPace Q1 revenue $14.5M (+27% YoY) and raises FY2023 guidance to $52-54M
Q1 revenue $14.5M, up 27% YoY and 13% sequentially; net loss narrowed to $10.4M from $11.5M.
NeuroPace director Greg Garfield will not seek reelection; Board to shrink to seven
Greg Garfield informed NeuroPace on April 11, 2023 he will not stand for reelection as director.
NeuroPace Q4 revenue $12.8M (+16% YoY); guides FY2023 revenue $50-52M
Q4 2022 revenue $12.8M (+16% YoY); initial implant revenue $9.8M (+15% YoY).
NeuroPace reports Q4 2022 preliminary revenue $12.8M (+16% YoY); appoints Dr. Uri Geiger to board
Q4 2022 total revenue expected ~$12.8M, up 16% from $11.0M in Q4 2021; initial implant revenue $9.8M (+15%).
NeuroPace Q3 revenue $11.2M (+8% YoY); lifts FY revenue guidance to $44.5-45.5M
Initial implant revenue $9.2M (+18% YoY); replacement revenue $1.9M vs $2.5M prior year.
Q2 total revenue $10.2M vs $12.6M YoY; initial implant revenue $8.0M, replacement $2.2M.
NeuroPace stockholders elect Favet, Fischer to board; ratify PwC as auditor
Michael Favet re-elected with 14,886,315 votes for, 1,376,600 withheld.
NeuroPace Q1 revenue $11.4M, net loss widens to $11.5M; guides FY2022 revenue $45-48M
Total revenue $11.4M (+2% YoY); initial implant rev $8.8M (+9%); replacement rev $2.6M (-16%).
NeuroPace reports 2021 revenue $45.2M (+10% YoY), Q4 net loss $10.7M
Full-year initial implant revenue $33.7M (+20% YoY); replacement revenue $11.5M (-12% YoY).
NeuroPace reports preliminary Q4 2021 revenue of $11.0M (+2% YoY); FY2021 $45.2M (+10% YoY)
Q4 2021 revenue ~$11.0M (+2% YoY); initial implant $8.5M (+10%), replacement $2.5M (-19%).
NeuroPace Q3 revenue drops 19% to $10.3M; net loss widens to $8.1M
Q3 total revenue $10.3M down 19% YoY; initial implant revenue $7.8M down 15%.
NeuroPace appoints Lisa Andrade as Class II director, replacing Evan Norton
Evan Norton resigned as Class II director effective Nov 1, 2021; no disagreement cited.
NeuroPace warns Q3 revenue uncertainty due to COVID-19 Delta variant procedure delays
Procedure volumes impacted in Q3 due to scheduling delays from COVID-19 Delta variant.
NeuroPace Q2 revenue $12.6M (+65% YoY); initial implants up 100%; reaffirms FY guidance
Total revenue $12.6M (+65% YoY); initial implant revenue $9.2M (+100% YoY, +14% QoQ).
the Company has appointed Patrick F. Williams as Chief Financial Officer, effective as of the Transition Date.
On June 20, 2025, Rebecca Kuhn departed from her position as Chief Financial Officer and Vice President, Finance and Administration of NeuroPace, Inc.
appointed Scott Huennekens as a director to fill the newly created vacancy, effective as of January 6, 2025.
On February 1, 2024, Irina Ridley notified NeuroPace, Inc. (the “Company”) that she was resigning from her role as the Company’s Chief Legal Officer and Corporate Secretary and that her last day of employment will be March 6, 2024 (the “Separation Date”).
On June 27, 2023, Michael Favet resigned from his position as Chief Executive Officer of NeuroPace, Inc. and as a member of NeuroPace’s board of directors
On June 27, 2023, Michael Favet resigned from his position as Chief Executive Officer of NeuroPace, Inc. and as a member of NeuroPace’s board of directors
On June 28, 2023, NeuroPace appointed Joel Becker as Chief Executive Officer and as a member of the Board, in each case effective as of the Separation Date.
On June 28, 2023, NeuroPace appointed Joel Becker as Chief Executive Officer and as a member of the Board, in each case effective as of the Separation Date.
On April 11, 2023, Greg Garfield notified NeuroPace, Inc. that he will not stand for reelection as a director to the Board of Directors (the “Board”) of NeuroPace, Inc.
On January 4, 2023, the NeuroPace Board appointed Dr. Uri Geiger as a Class III director, effective as of January 5, 2023.
On October 15, 2021, the Board appointed Lisa Andrade as a Class II director to fill the vacancy created by Mr. Norton’s resignation, effective as of November 1, 2021.
On October 14, 2021, Evan Norton, a Class II director, resigned from the Board of Directors (the “Board”) (including the Compensation Committee and Audit Committee) of NeuroPace, Inc., effective as of November 1, 2021.
Max materiality 0.90 · Median 0.65 · Most common event earnings